Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Discovering Opportunities: 3 Penny Stocks With Market Caps Over US$200M

In This Article:

As global markets navigate a mix of steady interest rates, fluctuating corporate earnings, and geopolitical uncertainties, investors are seeking opportunities in less conventional areas. Penny stocks, often seen as relics from past market eras, continue to offer intriguing possibilities for those willing to explore beyond the mainstream. These typically smaller or newer companies provide a blend of affordability and potential growth when backed by robust financial health.

Top 10 Penny Stocks

Name

Share Price

Market Cap

Financial Health Rating

Bosideng International Holdings (SEHK:3998)

HK$3.73

HK$42.97B

★★★★★★

DXN Holdings Bhd (KLSE:DXN)

MYR0.535

MYR2.64B

★★★★★★

Polar Capital Holdings (AIM:POLR)

£4.905

£468.49M

★★★★★★

Foresight Group Holdings (LSE:FSG)

£3.80

£455.09M

★★★★★★

Tristel (AIM:TSTL)

£3.70

£174.08M

★★★★★★

Datasonic Group Berhad (KLSE:DSONIC)

MYR0.395

MYR1.1B

★★★★★★

Hil Industries Berhad (KLSE:HIL)

MYR0.85

MYR292.11M

★★★★★★

MGB Berhad (KLSE:MGB)

MYR0.695

MYR414.16M

★★★★★★

Embark Early Education (ASX:EVO)

A$0.775

A$143.12M

★★★★☆☆

Helios Underwriting (AIM:HUW)

£2.23

£158.38M

★★★★★☆

Click here to see the full list of 5,707 stocks from our Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Viva Biotech Holdings

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Viva Biotech Holdings is an investment holding company that provides structure-based drug discovery services to biotechnology and pharmaceutical clients globally, with a market capitalization of approximately HK$1.69 billion.

Operations: The company generates revenue primarily from Drug Discovery Services, amounting to CN¥780.09 million, and Contract Development Manufacture Organisation (CDMO) and Commercialisation Services, contributing CN¥1.21 billion.

Market Cap: HK$1.69B

Viva Biotech Holdings, with a market cap of approximately HK$1.69 billion, is navigating the challenges typical of smaller stocks by leveraging its global presence and expanding operations. The establishment of a new branch in Boston enhances its strategic positioning within the biopharmaceutical industry. Despite being unprofitable, Viva maintains a positive cash flow and has sufficient runway for over three years, supported by CN¥1.9 billion in short-term assets exceeding short-term liabilities. However, increasing debt levels and negative return on equity highlight financial risks that investors should consider alongside growth potential from international expansion efforts.